Most reported cases of illness caused by C. sakazakii are in infants <2 months old (6, 7) . Premature infants and infants with underlying medical conditions are at the greatest risk for illness. Numerous outbreaks caused by C. sakazakii have been traced to contaminated powdered infant formula (8) . Powdered infant formula is not a sterile product, and the ability of C. sakazakii to tolerate dry conditions enables it to survive for long periods in the final powdered product (9) .
The screening of food (particularly powdered formula) was proposed to reduce the risk to neonatal and infant health (10, 11) . The most common syndromes of foodborne infection in infants include necrotizing enterocolitis (NEC), bacteremia, and meningitis (12, 13) . Examples of outbreaks of illness in hospital neonatal units caused by C. sakazakii associated with powdered infant formula have been compiled by Iversen and Forsythe (6) and by Lund (8) .
A few cases of illness (usually nongastrointestinal) in adults caused by C. sakazakii have been reported. In most of these cases the adults had underlying diseases, and no evidence of foodborne transmission was reported (14, 15) .
We performed a multicenter study of C. sakazakii infections in humans (EUCRONI) to determine the occurrence of C. sakazakii in clinical microbiology laboratories across Europe. We also assessed the extent of clonality for human C. sakazakii isolates.
Material and Methods

Study Design
EUCRONI consisted of national coordinators (EUCRONI study group members) from 24 countries in Europe. Coordinators had to actively approach all medical microbiology laboratories to collect human C. sakazakii isolates (1 per patient) in their respective countries during 2017. Human historical isolates (with isolation dates before 2017) were also accepted. The 24 participating countries were arbitrarily chosen to reflect a wide geographic and 
WGS Data Analysis
We de novo assembled raw reads by using SPAdes version 3.9.0 (17) for sequence analysis. We tested isolates in SeqSphere+ for Cronobacter-specific variant ampC (e.g., CSA-1, CSA-2, CMA-1, and CMA-2) (23).
Results
Strain Collection and Primary Species Identification
During the study period, 11 of 24 national coordinators ( Figure 1) Table 1 ).
Human C. sakazakii Isolates Collected in 2017
In total, 21 C. sakazakii isolates from 21 patients were collected in 2017 in 9 participating countries in Europe. Casefatality ratio (within 30 days after specimen collection) was 2 of 21 case-patients (Table 2 ).
Molecular Typing of Bacterial Isolates
The defined cgMLST gene set consisted of a total of 2,831 core and 1,017 accessory targets. Of 77 sequenced isolates, 59 isolates were confirmed as C. sakazakii. These isolates had on average 99.4% of good core genome targets (97.7% to 99.9%) (18) and revealed in total 17 different sequence types (STs) ( Table 3) .
Core genome comparison of 59 C. sakazakii isolates and the 3 reference strains revealed an average allelic difference of 2,402 and a maximum allelic difference of 2,724 ( Figure 2 ). Isolates clustered in the minimum- Twelve isolates belonged to ST4, of which 3 were confirmed isolates from infants. Two infant isolates belonged to an outbreak cluster with a common epidemiologic link detected in Austria in 2016; these isolates shared the same cgMLST profile and showed a maximum of 47 allelic differences to the historical reference strain NCTC 8155 (from milk, United Kingdom, 1950). This outbreak again affected 2 neonates (neonate A: female, age 22 days, positive blood culture, fatal outcome; neonate B: male, age 16 days, positive respiratory tract specimen) hospitalized in the neonatal intensive care unit of another hospital in Austria. The third infant isolate was a 2017 ST4 isolate from a case in Austria with a fatal outcome and was most closely related (302 allelic differences) to a historical strain from Denmark isolated in 2003.
Six clinical isolates assigned to ST8 consisted of 2 historical human isolates from Canada (date of isolation unknown). These 6 isolates shared the identical core genome profile and had 1 allelic difference to reference strain ATCC29544 (from an infant, United States, 1970).
Nine human isolates assigned to ST21 comprised historical outbreak cluster from France collected during 2010-2016. The outbreak included 3 female patients (mean age 62 years) and 5 male patients (mean age 68 years); initial specimens were abscess material from the digestive tract (n = 1), ascites fluid (n = 1), respiratory tract specimens (n = 2), and rectal swab specimens (n = 4). Eight of these 9 isolates showed the same core genome genes, and 1 yielded 1 allelic difference.
All 10 isolates assigned to ST155 belonged to a historical outbreak among infants in Belgium during 1997-1998; the isolates originated from blood cultures (n = 2), stool specimens (n = 2), rectal swab specimens (n = 4), and respiratory tract specimens (n = 2). The first positive sample was collected in November 1997; the remaining 9 specimens were obtained during August-September 1998. Eight of the 10 isolates shared the same cgMLST profile, and 2 had 1 allelic difference. In total, 27 of 38 historical isolates were most closely related (<1 allelic difference) to other historical isolates; 11 were singletons. All 21 isolates collected in 2017 were singletons, and no close relatedness was evident (>100 allelic differences) between historical isolates and isolates from 2017.
In Vitro and In Silico Antimicrobial Resistance Analysis
In vitro susceptibility testing of 21 human C. sakazakii isolates from 2017 revealed 20 C. sakazakii isolates that were susceptible to all 14 tested antibiotics (Appendix Table 2 The presence of variant ampC was confirmed for all 21 isolates. Seventeen isolates harbored CSA-2, and 4 isolates harbored CSA-1 (Appendix Table 2 ).
Discussion
The aim of our 2017 C. sakazakii study was to assess the occurrence of this opportunistic pathogen in countries of Europe, characterize the isolates, and recognize possible multinational outbreaks. Our finding that only 59 of 77 presumptive C. sakazakii isolates had the species-identification Figure 2 . Minimum-spanning tree of 59 Cronobacter sakazakii isolates, including 21 human isolates from 2017 and 38 historical human isolates, from 11 countries in Europe. Each circle represents isolates with an allelic profile based on the core genome multilocus sequence type, which consists of 2,831 alleles. Blue numbers indicate the allelic differences between isolates; isolates with closely related genotypes are shaded in gray. Isolates were colored according to classical multilocus sequence type, labeled with the country of isolation and the respective sample identification. Nodes encircled with a dotted red line were collected in 2017. Ireland additionally provided 7 historical isolates originating from Canada (n = 4), United States (n = 2), and Switzerland (n = 1). For comparison, sequence data of reference strains ATCC BAA-894 (United States, ST1), ATCC29544 (United States, ST8), and NCTC 8155 (United Kingdom, ST4) were included. ST, sequence type.
C. sakazakii confirmed at the central study center shows that correct identification of Cronobacter spp. is still a challenge for many routine laboratories.
The prevalence of reported C. sakazakii cases was low, with only 11 (45.8%) of 24 participating countries submitting C. sakazakii isolates. Clinical isolates from 2017 showed high genetic diversity, indicating that neither multinational nor national outbreaks occurred in 2017 in the 24 countries studied. However, characterization of the historical isolates obtained during this study confirmed occurrence of 4 previously unpublished historical outbreaks: 2 outbreaks from 2009 and 2016 in Austria, 1 from Belgium during 1997-1998, and 1 from France during 2010-2016. Hospitals affected by nosocomial C. sakazakii outbreaks might still be reluctant to publish possibly food-related outbreaks or nosocomial infections, especially in the case of affected infants and particularly in the case of related fatalities.
Strain typing using classical MLST identified a total of 17 STs among 59 sequenced C. sakazakii isolates. Our addition of a new ad hoc cgMLST scheme consisting of 2,831 core target genes provides more discriminative power for outbreak investigation and source tracking than the standard 7-loci MLST scheme.
The dominant STs found among our clinical C. sakazakii isolates from 2017 were ST4, ST17, ST1, and ST40, a distribution consistent with results from other studies (1). The medical literature often links C. sakazakii ST4 with powdered infant formula-associated outbreaks in infants (3). In our study, the sole strain (7750-17) affecting an infant (a 3-month-old baby boy who died) was ST4, isolated from a blood culture.
Antibiotic treatment is essential in the care of a patient with a confirmed Cronobacter infection. The traditional antibiotic regimen for Cronobacter spp. was ampicillin in combination with either gentamicin or chloramphenicol. In view of claimed resistance to ampicillin and most first-and second-generation cephalosporins, it has been suggested that carbapenems or third-generation cephalosporins be used with an aminoglycoside or trimethoprim/sulfamethoxazole (24) . In our study, antimicrobial resistance testing showed susceptibility to all tested antibiotics for 20 of 21 human isolates from 2017. In comparison to other members of the family Enterobacteriaceae, Cronobacter strains seem to be more susceptible against so-called "key access antibiotics" of the World Health Organization's Model List of Essential Medicines (25) , such as ampicillin, aminoglycosides, chloramphenicol, and third-generation cephalosporins (the last is included in the List of Essential Medicines only for specific, limited indications) (26) . For all isolates, we confirmed the presence of 1 of 4 tested ampC β-lactamase variants, which confer phenotypic resistance exclusively to first-generation cephalosporins (e.g., cephalothin) but not to ampicillin (23) . A few studies have reported Cronobacter isolates conferring multidrug resistance (26), a phenomenon observed in our study only for 1 strain from Slovenia.
Correct species identification within the Cronobacter group was a major challenge for 7 of 11 participating laboratories. This identification problem is consistent with numerous misidentifications reported in the literature (27, 28) . The discrepancies in correct Cronobacter spp. identification on a genus and species level between the study center in Austria and the primary testing laboratories using MALDI-TOF MS is probably attributable to outdated databases used by primary testing laboratories. Nevertheless, our study showed that the overall MALDI-TOF MS performance for Cronobacter spp. identification on the species level is insufficient and misleading. The databases contained data for C. sakazakii only, and therefore all 7 species of the genus Cronobacter were identified as C. sakazakii. In addition, although a database comment indicated that Cronobacter could only be identified on the genus level, the MALDI-TOF MS result simulated the highest identification score for C. sakazakii. This shortfall should be corrected by an update of the MALDI-TOF MS databases to enable accurate Cronobacter identification at the species level. In comparison, WGSbased species identification represents a major improvement to conventional identification methods and MALDI-TOF MS (29) . Therefore, we recommend the use of WGS-based identification tools and databases for identification of species within the Cronobacter group.
Adults were the main affected age group in our study. All but 2 of the isolates from 2017 originated from adults. This finding confirms the results from previous recent studies (14, 30) and contradicts statements in numerous medical textbooks, postulating that infants are more often affected than adults (8, (31) (32) (33) .
Our study has some limitations. Lack of information (e.g., detailed epidemiologic and clinical patient data) and misidentification on genus and species levels, might have played a role in underestimating the real prevalence rate; 13 of the 24 participating countries did not find or did not submit C. sakazakii isolates.
In conclusion, this C. sakazakii study in Europe revealed a high strain diversity, which points to highly diverse infection sources and an absence of national or multinational outbreaks in 2017. Correct identification of C. sakazakii still poses a diagnostic challenge to many laboratories, and the use of such imperfect detection systems might explain the low prevalence of reported clinical C. sakazakii isolates found in this study. WGS data must be used for accurate species identification and high-resolution strain typing. We recommend the inclusion of C. sakazakii as a notifiable organism by public health authorities.
